These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 2836501)

  • 1. Activation of the alternative complement pathway by EBV and the viral envelope glycoprotein, gp350.
    Mold C; Bradt BM; Nemerow GR; Cooper NR
    J Immunol; 1988 Jun; 140(11):3867-74. PubMed ID: 2836501
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CR2 is a complement activator and the covalent binding site for C3 during alternative pathway activation by Raji cells.
    Mold C; Nemerow GR; Bradt BM; Cooper NR
    J Immunol; 1988 Mar; 140(6):1923-9. PubMed ID: 2831273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutralization of influenza virus by normal human sera: mechanisms involving antibody and complement.
    Beebe DP; Schreiber RD; Cooper NR
    J Immunol; 1983 Mar; 130(3):1317-22. PubMed ID: 6822737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the alternative complement pathway by human B cell lymphoma lines is associated with Epstein-Barr virus transformation of the cells.
    McConnell I; Klein G; Lint TF; Lachmann PJ
    Eur J Immunol; 1978 Jul; 8(7):453-8. PubMed ID: 211040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alternative pathway of complement activation by human lymphoblastoid B and T cell lines.
    Praz F; Lesavre P
    J Immunol; 1983 Sep; 131(3):1396-9. PubMed ID: 6604099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding of the Epstein-Barr virus major envelope glycoprotein gp350 results in the upregulation of the TNF-alpha gene expression in monocytic cells via NF-kappaB involving PKC, PI3-K and tyrosine kinases.
    D'Addario M; Ahmad A; Morgan A; Menezes J
    J Mol Biol; 2000 May; 298(5):765-78. PubMed ID: 10801347
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activation of the alternative complement pathway by normal and transformed cells in homologous and heterologous sera.
    McConnell I; Gorman NT; Raniwalla J; Powell P
    Eur J Immunol; 1981 Feb; 11(2):126-32. PubMed ID: 6260511
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
    Hiramatsu M; Balow JE; Tsokos GC
    J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CR2 is the primary acceptor site for C3 during alternative pathway activation of complement on human peripheral B lymphocytes.
    Marquart HV; Svehag SE; Leslie RG
    J Immunol; 1994 Jul; 153(1):307-15. PubMed ID: 7515925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epstein-Barr Virus and its glycoprotein-350 upregulate IL-6 in human B-lymphocytes via CD21, involving activation of NF-kappaB and different signaling pathways.
    D'Addario M; Libermann TA; Xu J; Ahmad A; Menezes J
    J Mol Biol; 2001 May; 308(3):501-14. PubMed ID: 11327783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Studies of the mechanism of bacterial resistance to complement-mediated killing. V. IgG and F(ab')2 mediate killing of E. coli 0111B4 by the alternative complement pathway without increasing C5b-9 deposition.
    Joiner KA; Goldman RC; Hammer CH; Leive L; Frank MM
    J Immunol; 1983 Nov; 131(5):2563-9. PubMed ID: 6355296
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d.
    Nemerow GR; Mold C; Schwend VK; Tollefson V; Cooper NR
    J Virol; 1987 May; 61(5):1416-20. PubMed ID: 3033269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanism of complement inactivation by glycoprotein C of herpes simplex virus.
    Kostavasili I; Sahu A; Friedman HM; Eisenberg RJ; Cohen GH; Lambris JD
    J Immunol; 1997 Feb; 158(4):1763-71. PubMed ID: 9029114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Distinct patterns of viral antigen expression in Epstein-Barr virus and Kaposi's sarcoma-associated herpesvirus coinfected body-cavity-based lymphoma cell lines: potential switches in latent gene expression due to coinfection.
    Callahan J; Pai S; Cotter M; Robertson ES
    Virology; 1999 Sep; 262(1):18-30. PubMed ID: 10489337
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-independent activation of the classical pathway of complement by Epstein-Barr virus.
    Martin H; McConnell I; Gorick B; Hughes-Jones NC
    Clin Exp Immunol; 1987 Mar; 67(3):531-6. PubMed ID: 3038440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of an activated b lymphocyte-associated surface moiety defined by the B2 monoclonal antibody by ebv conversion of an EBV-negative lymphoma line (Ramos): differential effect of transforming (B95-8) and nontransforming (P3HR-1) EBV substrains.
    Klein G; Ehlin-Henriksson B; Schlossman SF
    J Immunol; 1983 Apr; 130(4):1985-9. PubMed ID: 6300235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of a 70-kDa, EBV gp350/220-binding protein on HSB-2 T cells.
    Hedrick JA; Lao Z; Lipps SG; Wang Y; Todd SC; Lambris JD; Tsoukas CD
    J Immunol; 1994 Nov; 153(10):4418-26. PubMed ID: 7963519
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune activation suppresses initiation of lytic Epstein-Barr virus infection.
    Ladell K; Dorner M; Zauner L; Berger C; Zucol F; Bernasconi M; Niggli FK; Speck RF; Nadal D
    Cell Microbiol; 2007 Aug; 9(8):2055-69. PubMed ID: 17419714
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Importance of the integrity of the inter-heavy-chain disulphide bond of rabbit IgG in the activation of the alternative pathway of human complement by the F(ab')2 region of rabbit IgG antibody in immune aggregates.
    Gadd KJ; Reid KB
    Immunology; 1981 Jan; 42(1):75-82. PubMed ID: 6780451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation of Epstein Barr-virus and studies of its neutralization by human IgG and complement.
    Nemerow GR; Cooper NR
    J Immunol; 1981 Jul; 127(1):272-8. PubMed ID: 6263973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.